Mirum Pharmaceuticals (MIRM) Interest Expenses (2019 - 2026)

Mirum Pharmaceuticals' Interest Expenses history runs 8 years deep, the most recent figure standing at $26.7 million for Q1 2026.

• On a quarterly basis, Interest Expenses fell 79.65% year-over-year to $26.7 million in Q1 2026; TTM through Mar 2026 was $26.7 million, a 79.65% decrease from a year earlier, with the FY2025 full-year figure at $480.0 million, up 105.86% from the prior year.
• Interest Expenses improved to $26.7 million in Q1 2026 per MIRM's latest filing, from $8.1 million in the prior quarter.
• Across five years, Interest Expenses topped out at $293.7 million in Q2 2025 and bottomed at $3.6 million in Q4 2024.
• The 5-year median for Interest Expenses is $27.3 million (2022), against an average of $71.9 million.
• Across the five-year window, Interest Expenses surged 3913.88% in 2023 and slumped 79.65% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $4.4 million in 2022, then soared by 227.62% to $14.3 million in 2023, then plunged by 74.94% to $3.6 million in 2024, then jumped by 125.31% to $8.1 million in 2025, then soared by 231.62% to $26.7 million in 2026.
• Per Business Quant, the three latest MIRM Interest Expenses figures stand at $26.7 million (Q1 2026), $8.1 million (Q4 2025), and $131.4 million (Q3 2025).